Biosplice Therapeutics Stock

biosplice.comHealthcare / BioTech & PharmaFounded: 2008

Biosplice Therapeutics is developing therapies through alternative pre-mRNA splicing, which can allow for the elimination of harmful proteins. The company's current pipeline focuses on osteoarthritis and oncology. Biosplice Therapeutics was founded in 2008 by Osman Kibar Ph.D., Dennis Carson, Richard Schwab, and John Hood Ph.D. and is headquartered in San Diego, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Biosplice Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Biosplice Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biosplice Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Biosplice Therapeutics investors also invested in these private companies

Team

Management Team

Cevdet Samikoglu
Chief Executive Officer & Board Member
Erich Horsley
Chief Financial Officer & Chief Business Officer
Scott Bulcao
Chief Legal Officer
Osman Kibar Ph.D
Co-Founder & Executive Chairman
Yusuf Yazici MD
Chief Medical Officer

Board Members

Chidozie Ugwumba
SymBiosis Capital Management
Gur Roshwalb MD
aMoon Fund
Joy Ghosh Ph.D
Eventide Asset Management
Kyle Rasbach Ph.D
Eventide Asset Management

Biosplice Therapeutics’ stock FAQs

plusminus

Can you buy Biosplice Therapeutics’ stock?

Biosplice Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Biosplice Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Biosplice Therapeutics’ stock?

Yes, you can sell stock of a private company like Biosplice Therapeutics. Forge can help you sell your Biosplice Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus

What is Biosplice Therapeutics’ stock price?

Biosplice Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Biosplice Therapeutics’ private market stock price with Forge Data.
plusminus

What is Biosplice Therapeutics’ stock ticker symbol?

Biosplice Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial

Biosplice Therapeutics, a clinical-stage biotech company pioneering first-in-class small molecule therapeutics, has announced potential structure-modifying highlights from an ongoing long-term extension study for its knee osteoarthritis (OA) drug candidate, lorecivivint.

The osteoarthritis market is expected to increase to $3.8bn in 2031

The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 billion in 2031, at a compound annual growth rate (CAGR) of 4.4%.
Updated on: Jun 22, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.